J. Luk

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib[S]

R. Krauss, C. Pinto, J. Wagner, 2012, Journal of Lipid Research.

The effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin

W. Kraft, J. Wagner, A. van Hecken, 2011, Platelets.

Pharmacokinetics of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, in Patients With Moderate Hepatic Impairment

J. Wagner, K. Lasseter, T. Marbury, 2011, Journal of clinical pharmacology.

Jefferson Digital

Inge, W. Kraft, J. Wagner, 2022 .